Skip to main content
. 2017 Aug 10;8(59):100734–100745. doi: 10.18632/oncotarget.20140

Table 3. Adverse events.

Adverse events (%) All grades n (%) Grade ≥ 3 n (%)
Fatigue 12 (63.15) 0 (0)
Headache/Dizzy 3 (15.79) 0 (0)
Diarrhea 11 (57.89) 1 (5.26)
Anorexia 9 (47.37) 0 (0)
Vomit 0 (0) 0 (0)
Stomachache 0 (0) 0 (0)
Nausea 4 (21.05) 0 (0)
Alimentary tract hemorrhage 0 (0) 0 (0)
Dysphagia 0 (0) 0 (0)
Pharyngolaryngeal pain 1 (5.26) 0 (0)
Dyspepsia 6 (31.58) 0 (0)
Mucositis oral 3 (15.79) 0 (0)
Dysgensia 0 (0) 0 (0)
HFSR 17 (89.47) 1 (5.26)
Hypertension 15 (78.95) 0 (0)
Proteinuria 6 (31.58) 0 (0)
Elevated transaminase 1 (5.26) 0 (0)
Hyperbilirubinemia 1 (5.26) 0 (0)
Elevated GGT 0 (0) 0 (0)
Alkaline phosphatase 0 (0) 0 (0)
Hypoproteinemia 2 (10.53) 0 (0)
Leukopenia 0 (0) 0 (0)
Neutropenia 0 (0) 0 (0)
Aglobulism 0 (0) 0 (0)
Thrombocytopenia 5 (26.32) 0 (0)
Hoarseness 1 (5.26) 0 (0)

HFSR: hand-foot-skin reaction; GGT: gamma-glutamyl transpeptidase.